Neuroprotective and neurotoxic effects of endocannabinoid-like compounds, N-arachidonoyl dopamine and N-docosahexaenoyl dopamine in differentiated cultures of induced pluripotent stem cells derived from patients with Parkinson's disease
Type of Study: Laboratory Study
Year of Pub: 2021
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Type of Study: Animal Study
Year of Pub: 2021
Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases
Type of Study: Meta-analysis
Year of Pub: 2021
β-Caryophyllene exerts protective antioxidant effects through the activation of NQO1 in the MPTP model of Parkinson's disease
Type of Study: Animal Study
Year of Pub: 2021
Cannabis in Parkinson's Disease: The Patients' View
Type of Study: Meta-analysis
Year of Pub: 2021
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
Type of Study: Meta-analysis
Year of Pub: 2020
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease
Type of Study: Double Blind Human Trial
Year of Pub: 2020
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review
Type of Study: Meta-analysis
Year of Pub: 2020
Biological bases for a possible effect of cannabidiol in Parkinson's disease
Type of Study: Meta-analysis
Year of Pub: 2020
Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway
Type of Study: Laboratory Study
Year of Pub: 2020
Medical cannabis as an alternative therapeutics for Parkinsons' disease: Systematic review
Type of Study: Meta-analysis
Year of Pub: 2020
Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions
Type of Study: Meta-analysis
Year of Pub: 2020
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease
Type of Study: Animal Study
Year of Pub: 2020
Cannabidiol in Parkinson’s disease
Type of Study: Meta-analysis
Year of Pub: 2020
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease
Type of Study: Meta-analysis
Year of Pub: 2020
Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Type of Study: Animal Study
Year of Pub: 2020
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia
Type of Study: Animal Study
Year of Pub: 2020
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB 1 R gene expression and reduces dyskinesias in a rat model of Parkinson's disease
Type of Study: Animal Study
Year of Pub: 2020
Expression of GPR55 and either cannabinoid CB 1 or CB 2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Type of Study: Animal Study
Year of Pub: 2020
Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases
Type of Study: Meta-analysis
Year of Pub: 2020
Pros and Cons of Marijuana in Treatment of Parkinson’s Disease
Type of Study: Meta-analysis
Year of Pub: 2019
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Type of Study: Meta-analysis
Year of Pub: 2019
Evidence for the use of cannabinoids in Parkinson's disease
Type of Study: Meta-analysis
Year of Pub: 2019
Marijuana for Parkinson’s Disease?
Type of Study: Meta-analysis
Year of Pub: 2019
The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease
Type of Study: Meta-analysis
Year of Pub: 2019
Regional Changes in the Type 1 Cannabinoid Receptor Are Associated With Cognitive Dysfunction in Parkinson's Disease
Type of Study: Meta-analysis
Year of Pub: 2019
Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US
Type of Study: Meta-analysis
Year of Pub: 2019
β-Caryophyllene (BCP) ameliorates MPP+ induced cytotoxicity.
Type of Study: Laboratory Study
Year of Pub: 2018
Evaluation of Phytomedicinal Potential of Perillyl Alcohol in an in Vitro Parkinson's Disease Model
Type of Study: Laboratory Study
Year of Pub: 2018
Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease. Induced by MPTP.
Type of Study: Animal Study
Year of Pub: 2017
Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease.
Type of Study: Human Trial
Year of Pub: 2017
Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Type of Study: Animal Study
Year of Pub: 2016
Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.
Type of Study: Animal Study
Year of Pub: 2016
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Type of Study: Animal Study
Year of Pub: 2016
Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.
Type of Study: Meta-analysis
Year of Pub: 2016
Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Type of Study: Animal Study
Year of Pub: 2016
Protective Effect of Geraniol on the Transgenic Drosophila Model of Parkinson's Disease
Type of Study: Animal Study
Year of Pub: 2016
Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone
Type of Study: Animal Study
Year of Pub: 2016
The neuroprotection of cannabidiol against MPP(+)-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.
Type of Study: Laboratory Study
Year of Pub: 2015
Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
Type of Study: Meta-analysis
Year of Pub: 2015
Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.
Type of Study: Laboratory Study
Year of Pub: 2015
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Type of Study: Animal Study
Year of Pub: 2014
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.
Type of Study: Meta-analysis
Year of Pub: 2014
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
Type of Study: Human Trial
Year of Pub: 2014
Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.
Type of Study: Laboratory Study
Year of Pub: 2012
Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.
Type of Study: Laboratory Study
Year of Pub: 2012
WIN55,212-2, a Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss in the MPTP Mouse Model of Parkinson’s Disease.
Type of Study: Animal Study
Year of Pub: 2009
Cannabidiol for the treatment of psychosis in Parkinson's disease
Type of Study: Human Trial
Year of Pub: 2009
Cannabinoids and neuroprotection in basal ganglia disorders.
Type of Study: Meta-analysis
Year of Pub: 2007
Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms.
Type of Study: Meta-analysis
Year of Pub: 2004
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study
Type of Study: Double Blind Human Trial
Year of Pub: 2001